In a significant pharmaceutical patent ruling, Canada’s Federal Court of Appeal dismissed Pharmascience’s appeal in Case No. A-69-22, affirming that Pharmascience’s proposed generic version of INVEGA SUSTENNA (paliperidone palmitate injectable suspension) would directly infringe and induce infringement of Janssen’s patents, including CA2655335A1. The court awarded costs of $10,000 to Janssen, all-inclusive, and confirmed that both physicians and patients administering the 75 mg-eq. dosage would be direct infringers, with Pharmascience serving as the inducing party. The case was filed March 31, 2022, and closed January 12, 2024.

This ruling carries substantial implications for generic pharmaceutical manufacturers seeking to enter the long-acting injectable antipsychotic market in Canada. IP strategists, pharmaceutical counsel, and R&D leaders monitoring biosimilar and generic entry pathways for atypical antipsychotics should take note: the Federal Court of Appeal’s affirmation of the induced infringement doctrine in a product-dosage context reinforces the breadth of protection available to innovator pharmaceutical companies under Canadian patent law and raises the bar for design-around strategies in this drug class.

Case Overview

The Parties

The Patents at Issue

The patents at issue, including CA2655335A1, cover formulations and dosing regimens for paliperidone palmitate, the active ingredient in INVEGA SUSTENNA — a long-acting injectable antipsychotic administered monthly. The claims address specific dosage strengths, including the 75 mg-eq. dose, and the methods by which physicians and patients administer the drug. These patents protect not only the chemical formulation but also the clinical use protocols that define how the treatment is delivered in practice.

• • CA1051135A
• • CA2655335A1

Legal Representation

Plaintiff Counsel: Aitken Klee LLP (lead: Marcus Klee)
Defendant Counsel: Belmore Neidrauer LLP (lead: Marian Wolanski)

Litigation Timeline & Procedural History

The case was heard by the Canada Federal Court of Appeal, a superior appellate court that reviews decisions of the Federal Court of Canada on matters including patent infringement under the Patented Medicines (Notice of Compliance) Regulations and general patent law. This appellate proceeding is categorized under ‘other’ trial level, reflecting its nature as a direct appeal from a prior Federal Court ruling rather than an initial trial, and it falls within the specialized framework of Canadian pharmaceutical patent litigation governing generic drug market entry.

The case spanned approximately 652 days from filing on March 31, 2022, to closure on January 12, 2024 — a duration typical for appellate pharmaceutical proceedings in Canada involving complex claim construction and inducement questions. The appeal was resolved through a declaratory judgment dismissal rather than a remand or settlement, indicating the appellate panel found no reversible error in the Federal Court’s original findings on direct and induced infringement across all claims of the 335 Patent. The $10,000 agreed-upon costs award reflects a negotiated costs arrangement, which is common in Canadian appellate pharmaceutical matters.

The Verdict & Legal Analysis

Outcome

The Federal Court of Appeal dismissed Pharmascience’s appeal in its entirety, affirming that all claims of the CA2655335 (335 Patent) would be directly infringed by physicians and patients using Pharmascience’s generic version of INVEGA SUSTENNA at 75 mg-eq. doses, and that Pharmascience would induce all such infringement. The court awarded costs to Janssen in the agreed all-inclusive amount of $10,000. No damages beyond costs were adjudicated at this appellate stage, as the proceeding focused on the patent validity and infringement determination rather than a quantum of compensatory relief.

Verdict Cause Analysis

The appellate panel’s declaratory judgment rested on several distinct legal findings regarding the scope of infringement and Pharmascience’s role as an inducing party:

• The Federal Court of Appeal confirmed that direct infringement of all claims of the 335 Patent would be committed by physicians and patients administering Pharmascience’s generic paliperidone palmitate at the 75 mg-eq. dosage — not by Pharmascience itself.
• Pharmascience was found to be the inducing party for all direct infringement arising from the use of its generic product, as its market entry and product labeling would knowingly cause third parties to perform the patented method.
• The appellate panel found no error in the Federal Court’s application of the inducement doctrine to the non-physician-administered dosage claims (claims 17 to 32) or to the remaining claims of the 335 Patent.
• The appeal was dismissed on all grounds, signaling that the lower court’s claim construction and infringement analysis were upheld without qualification, reinforcing the breadth of Janssen’s patent claims across the full dosing regimen.

Legal Significance

1. 1. This decision affirms that Canadian courts will apply the induced infringement doctrine robustly in pharmaceutical dosing cases, holding generic manufacturers responsible for infringement committed downstream by healthcare providers and patients who rely on the generic product’s labeling and dosing instructions.
2. 2. The ruling confirms that method-of-treatment and dosing claims in Canadian pharmaceutical patents can effectively block generic entry even where the generic manufacturer itself does not directly perform the patented act, expanding the practical scope of innovator patent protection.
3. 3. For pending cases involving long-acting injectables and other dosage-form patents, this decision signals that Canadian appellate courts will carefully scrutinize whether a generic manufacturer’s product labeling and marketing materials are sufficient to establish the knowledge and inducement elements required for liability.

Strategic Takeaways

For Patent Attorneys:

• When prosecuting Canadian pharmaceutical patents, ensure that method-of-treatment and dosing claims are drafted to cover acts performed by physicians, patients, and caregivers, as the Federal Court of Appeal has confirmed these parties can be direct infringers whose acts are attributed back to a generic manufacturer as inducement.
• Generic manufacturers facing similar PMNOC proceedings should scrutinize product monographs and package inserts prior to filing, as courts will treat these documents as evidence of the manufacturer’s intent to induce infringement of specific dosing method claims.
• Counsel defending generic entry should consider challenging the validity of dosing-regimen claims at the Federal Court level and on appeal, as this case confirms that once infringement is established across all claims, the appellate court is unlikely to disturb those findings without clear error.
• The agreed-upon costs mechanism used here ($10,000 all-inclusive) reflects a practical approach to managing appellate costs in Canadian pharmaceutical litigation; negotiating costs caps early can limit financial exposure for appellants even in unsuccessful appeals.

For IP Professionals:

• In-house IP teams at generic pharmaceutical companies should implement a pre-filing review protocol that maps every dosing instruction in the proposed product monograph against all method-of-treatment and dosing claims in relevant innovator patents, given that Canadian courts will treat labeling as direct evidence of inducement intent.
• Portfolio managers for innovator pharmaceutical companies should consider filing layered dosing-regimen claims in Canadian applications for long-acting injectables, as this case demonstrates that broad claim coverage across multiple dosage strengths can effectively foreclose generic market entry at the appellate level.

For R&D Teams:

• R&D teams developing alternative long-acting injectable antipsychotic formulations should conduct Freedom-to-Operate analysis specifically focused on dosing regimen and administration method claims, not only compound claims, as the Pharmascience v. Janssen outcome confirms these claim types are enforceable to block generic market entry in Canada.
• Engineering and formulation teams working on paliperidone or related atypical antipsychotic delivery systems should explore alternative dose strengths and administration intervals that fall outside the specific dosing windows claimed in CA2655335A1 to reduce induced infringement exposure before clinical development advances.